#1 Clinical Trials Search in Europe

Study of Pembrolizumab and Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of cancer called muscle-invasive bladder cancer. This is a condition where cancer cells have spread into the muscle wall of the bladder. The study is exploring the effects of two medications, pembrolizumab and sacituzumab govitecan, on patients who cannot receive or choose not to receive a common chemotherapy treatment known as cisplatin-based chemotherapy. Pembrolizumab, also known by its code name MK-3475, is a medication that helps the immune system fight cancer cells. Sacituzumab govitecan, also referred to as IMMU-132, is a type of treatment that combines an antibody with a drug to target and kill cancer cells.

The purpose of this study is to see if the combination of pembrolizumab and sacituzumab govitecan can lead to a complete response, meaning no signs of cancer are found in the tissue after surgery. Participants in the study will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will follow a specific schedule where patients will receive the treatment over a period of time, and their health will be monitored closely to observe any changes or side effects. The study aims to understand how well these medications work together and how safe they are for patients.

Throughout the study, researchers will look at how many patients have a complete response to the treatment, as well as monitor any side effects that occur. They will also track how long patients live without the cancer getting worse, known as progression-free survival, and overall survival, which is the length of time patients live after starting the treatment. This information will help determine the effectiveness and safety of using pembrolizumab and sacituzumab govitecan for treating muscle-invasive bladder cancer.

1 initial assessment

Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes a review of medical history and current health status.

A series of tests such as CT, PET/CT, and mpMRI will be performed to assess the stage of muscle-invasive bladder cancer.

2 consent and preparation

Written informed consent will be obtained after explaining the study details.

For male participants, an agreement to use contraception from the first dose through three months after the last dose is required.

Female participants of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use two methods of birth control during the study and for six months after the last dose.

3 treatment initiation

The treatment involves two medications: sacituzumab govitecan and pembrolizumab, both administered as solutions for infusion.

Sacituzumab govitecan is given intravenously. The specific dosage and frequency will be determined by the study team.

Pembrolizumab is also administered intravenously. The dosage and frequency will be specified by the study team.

4 treatment monitoring

Regular monitoring will occur throughout the treatment period to assess the response and any side effects.

Safety and tolerability will be evaluated, and any adverse events will be recorded and managed according to established criteria.

5 surgery preparation

Participants will be prepared for radical cystectomy (RC), a surgical procedure to remove the bladder, as part of the treatment plan.

The timing and specific preparations for surgery will be communicated by the medical team.

6 post-treatment evaluation

After the treatment and surgery, a thorough evaluation will be conducted to determine the presence of any remaining cancer cells.

The primary goal is to achieve a complete pathological response, meaning no viable tumor cells are found.

7 follow-up

Long-term follow-up will be conducted to monitor overall survival and progression-free survival.

Regular check-ups and tests will be scheduled to ensure ongoing health and to detect any recurrence of cancer.

Who Can Join the Study?

  • Must be a female or male over 18 years old and able to understand and sign a consent form.
  • Men must agree to use a reliable method of birth control from the start of the study until 3 months after the last dose of the study medication.
  • Must have a specific stage of bladder cancer, known as clinical stage T2-T4aN0M0, confirmed by imaging tests like CT, PET/CT, or MRI.
  • Must agree to undergo a surgery called RC (removal of the bladder).
  • Must be unable to receive or choose not to receive a type of chemotherapy called cisplatin-based chemotherapy.
  • Must have a confirmed diagnosis of a type of bladder cancer called urothelial carcinoma. If the cancer has mixed types, at least 50% must be urothelial carcinoma.
  • Must be in good enough health to undergo the bladder removal surgery, according to local health guidelines.
  • Must have an ECOG performance status score of 0 or 1, which means being fully active or having some symptoms but still able to carry out light work.
  • Must have adequate blood counts without needing recent blood transfusions or medications to boost blood cell production. This includes hemoglobin levels of at least 9 g/dL, a type of white blood cell count (ANC) of at least 1,500/mm3, and platelet count of at least 100,000/μL.
  • Must have adequate liver function, with bilirubin levels at or below 1.5 times the upper limit of normal, and AST and ALT levels at or below 2.5 times the upper limit of normal (or 5 times if there are known liver metastases), and serum albumin levels above 3 g/dL.
  • Must have a creatinine clearance of at least 30 mL/min, which is a measure of kidney function.
  • Women who can have children must have a negative pregnancy test within 72 hours before starting the study medication and must not be breastfeeding. If the urine test is positive or unclear, a blood test will be required.
  • Women who can have children must agree to use two methods of birth control, be surgically sterile, or abstain from heterosexual activity during the study and for 6 months after the last dose of study medication. Women who can have children are those who have not had surgery to prevent pregnancy or have not stopped having periods for more than 2 years.

Who Cannot Join the Study?

  • Patients who have received any other cancer treatment within the last 4 weeks.
  • Patients with a history of severe allergic reactions to the study drugs.
  • Patients with uncontrolled infections.
  • Patients with other active cancers.
  • Patients who are pregnant or breastfeeding.
  • Patients with significant heart problems.
  • Patients with severe liver or kidney disease.
  • Patients with a history of autoimmune diseases, which are conditions where the immune system attacks the body.
  • Patients who have received a live vaccine within 30 days before the start of the study.
  • Patients with a history of drug or alcohol abuse.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Ospedale San Raffaele S.r.l. Milan Italy

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Italy Italy
Not recruiting
01.06.2021

Trial locations

Investigated drugs:

Pembrolizumab is a type of medication known as an immunotherapy. It works by helping your immune system fight cancer cells. In this trial, pembrolizumab is used to help your body recognize and attack the bladder cancer cells more effectively.

Sacituzumab govitecan is a targeted therapy that combines an antibody with a chemotherapy drug. The antibody part of the medication helps deliver the chemotherapy directly to the cancer cells, which can help reduce the growth of the tumor. In this trial, sacituzumab govitecan is used alongside pembrolizumab to enhance the treatment’s effectiveness against bladder cancer.

Investigated diseases:

Muscle-invasive bladder cancer – Muscle-invasive bladder cancer is a type of bladder cancer that has spread into the muscle layer of the bladder wall. It typically begins in the cells lining the bladder and progresses deeper into the bladder tissue. As the cancer grows, it can invade surrounding tissues and organs, potentially spreading to lymph nodes and other parts of the body. The disease often presents with symptoms such as blood in the urine, frequent urination, and pain during urination. Over time, the cancer may cause more severe symptoms and complications as it advances. The progression of muscle-invasive bladder cancer can vary, with some cases advancing more rapidly than others.

Trial ID:
2024-514569-20-00
Protocol code:
SURE-02
NCT ID:
NCT05535218
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study of MK-3120 for patients with high-risk non-muscle invasive bladder cancer who have not received or have received BCG treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Greece Italy The Netherlands +2